Efficacy of Dexamethasone Versus N-acetylcysteine in preventing post-embolization syndrome after trans arterial chemoembolization in hepatocellular carcinoma: A randomized controlled trial

Phase 2

• Conditions: Hepatocellular carcinoma who underwent conventional TACE.; PES; HCC; Dexamethasone; N-acetylcysteine; liver decompensation

• Registration Number: TCTR20240816008
• Lead Sponsor: FACULTY OF MEDICINE VAJIRA HOSPITAL foundation for research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-08-16
• Last Update Posted: 19 August 2024
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

age 18-70 yrs old was diagnosis of Hepatocellular carcinoma who underwent conventional TACE

Exclusion Criteria

decompensated cirrhosis
congestive heart failure with or without respiration failure
severe comorbidity (uncontrolled DM, HbA1C >8.5, untreated HIV infection)
drug allergen to N-acetylcysteine, dexamethasone
pregnancy
previous use of NSIADs /steroids / N-acetylcysteine
contraindication of TACE
ongoing sepsis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of Post embolism syndrome in 48 hr after TACE PES was defined by South West Oncology Group toxicity code grading of more than 2 that was calculated using incidence of fever, nausea, vomiting, and pain.

Secondary Outcome Measures

Name	Time	Method
post-Trans arterial chemoembolization liver decompensation in 48 hr after TACE liver decompensation